Carregant...
The age of enlightenment in melanoma immunotherapy
An updated survival analysis by Callahan et al. published in the February 1, 2018 issue of the Journal of Clinical Oncology reported a 3-year overall survival (OS) rate of 63% for 94 patients with previously treated or untreated advanced melanoma who received ipilimumab and nivolumab as concurrent t...
Guardat en:
| Publicat a: | J Immunother Cancer |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6103975/ https://ncbi.nlm.nih.gov/pubmed/30134977 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0397-8 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|